No description available.

El objetivo de esta Tesis ha sido profundizar en el estudio del desarrollo del complejo claustroamigdalino en ratón. Para ello hemos estudiado: 1) cuales de sus componentes derivan del palio lateral o ventral, en base a expresión diferencial de genes reguladores Dbx1, Lhx9, Lhx2, Lmo3, Lmo4, Cadherina 8 y Emx1 durante el desarrollo embrionario; 2) el desarrollo de las interneuronas del complejo claustroamigdalino que contienen proteínas ligadoras de calcio (incluyendo el desarrollo de sus circuitos locales); 3) el origen histogenético de dichas interneuronas, mediante cultivos organotípicos y el análisis del ratón transgénico Nkx2.1-Cre/Rosa26-GFP (Kessaris y col. 2006). Nuestros datos permiten distinguir los componentes paliales laterales o ventrales del complejo, que contienen múltiples subtipos de interneuronas con orígenes en distintas subdivisiones del subpalio. Esto abre las puertas a futuras investigaciones sobre la conectividad y función de cada subtipo de interneurona, y sobre su grado de implicación en los desórdenes neuropsiquiátricos. / The objective of this Doctoral Thesis was to deepen in the study of the development of the claustroamygdaloid complex in mouse. For that, we pursued to study: 1) which components derive from either the lateral or ventral pallium based on differential expression of regulatory genes (Dbx1, Lhx9, Lhx2, Lmo3, Lmo4, Cadherina 8 y Emx1) during embryonic development; 2) the development of interneurons of the claustroamygdaloid complex that contain calcium binding proteins (including the development of its local circuits); 3) the histogenetic origin of these interneurons, by means of organotypic cultures and analysis of the transgenic mouse Nkx2.1-Cre/Rosa26-GFP (Kessaris and col. 2006). Our data allowed the distinction between lateral and ventral pallial components of the complex, which contain multiple subtypes of interneurons with origins in different subpallial subdivisions. This opens new venues for future investigations on the connectivity and function of each interneuron subtype, and on their involvement in neuropsychiatric disorders.

Chronic kidney disease (CKD) and acute kidney injury (AKI) are major public health problems. It is important to be able to identify those at high risk of adverse outcome, CKD progression and associated cardiovascular disease. The aim of the thesis was to study novel promising biomarkers, their relationship to kidney function, chronic inflammation and/or cardiovascular risk - placental growth factor (PlGF), pregnancy associated plasma protein A (PAPP-A), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), soluble receptor for advanced glycation end products (sRAGE), calcium binding protein S100A12 or extracellular newly identified RAGE binding protein (EN-RAGE), and high mobility group box protein-1 (HMGB-1) in patients with renal diseases including CKD, haemodialysis (HD), AKI patients, and healthy controls for comparison. First study revealed that PlGF is elevated in patients with decreased renal function. Second study demonstrated the association of MMP-2 and PAPP-A with proteinuria in patients with CKD. Moreover, serum MMP-2, MMP-9 and PAPP-A levels significantly differed in patients with various nephropathies. EN-RAGE levels are not elevated in patients with CKD, but are related to inflammatory status. PAPP-A, EN-RAGE and HMGB-1 levels are significantly elevated, but sRAGE and PlGF...

Chronic kidney disease (CKD) and acute kidney injury (AKI) are major public health problems. It is important to be able to identify those at high risk of adverse outcome, CKD progression and associated cardiovascular disease. The aim of the thesis was to study novel promising biomarkers, their relationship to kidney function, chronic inflammation and/or cardiovascular risk - placental growth factor (PlGF), pregnancy associated plasma protein A (PAPP-A), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), soluble receptor for advanced glycation end products (sRAGE), calcium binding protein S100A12 or extracellular newly identified RAGE binding protein (EN-RAGE), and high mobility group box protein-1 (HMGB-1) in patients with renal diseases including CKD, haemodialysis (HD), AKI patients, and healthy controls for comparison. First study revealed that PlGF is elevated in patients with decreased renal function. Second study demonstrated the association of MMP-2 and PAPP-A with proteinuria in patients with CKD. Moreover, serum MMP-2, MMP-9 and PAPP-A levels significantly differed in patients with various nephropathies. EN-RAGE levels are not elevated in patients with CKD, but are related to inflammatory status. PAPP-A, EN-RAGE and HMGB-1 levels are significantly elevated, but sRAGE and PlGF...